92 related articles for article (PubMed ID: 11261278)
1. [High dosage chemotherapy with autologous stem cell transplantation in multiple myeloma].
Ruckser R; Kier P; Buxhofer V; Kittl E; Tatzreiter G; Vedovelli H; Zelenka P; Hübl G; Hinterberger W
Acta Med Austriaca Suppl; 2000; 52():40-2. PubMed ID: 11261278
[TBL] [Abstract][Full Text] [Related]
2. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
[TBL] [Abstract][Full Text] [Related]
3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
4. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ
Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931
[TBL] [Abstract][Full Text] [Related]
8. [Autologous peripheral blood stem cell transplantation for Japanese multiple myeloma patients: results of a feasibility study].
Nakamura Y; Sakamaki H; Mukai H; Kojima H; Tomiyama J; Mori S; Hiruma K; Nakamura N; Toyota S; Hamaguchi H; Dans K; Mitani K; Saito K
Rinsho Ketsueki; 2004 Jul; 45(7):524-9. PubMed ID: 15359911
[TBL] [Abstract][Full Text] [Related]
9. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
[TBL] [Abstract][Full Text] [Related]
10. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
11. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
12. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients.
Powles R; Sirohi B; Kulkarni S; Bhagwati N; Saso R; Raje N; Horton C; Singhal S; Mehta J; Treleaven J
Bone Marrow Transplant; 2000 May; 25(9):949-56. PubMed ID: 10800062
[TBL] [Abstract][Full Text] [Related]
13. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.
Chen CI; Abraham R; Tsang R; Crump M; Keating A; Stewart AK
Bone Marrow Transplant; 2001 Jan; 27(2):177-82. PubMed ID: 11281387
[TBL] [Abstract][Full Text] [Related]
14. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
15. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
[TBL] [Abstract][Full Text] [Related]
16. [Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results].
Schmid C; Weisser M; Ledderose G; Stötzer O; Schleuning M; Kolb HJ
Dtsch Med Wochenschr; 2002 Oct; 127(42):2186-92. PubMed ID: 12397547
[TBL] [Abstract][Full Text] [Related]
17. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
19. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].
Shimokawa T; Kajiguchi T; Saito M; Kojima Y; Takeyama H
Gan To Kagaku Ryoho; 2003 Feb; 30(2):251-4. PubMed ID: 12610874
[TBL] [Abstract][Full Text] [Related]
20. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
